Targeting a hyperactivated MAPK pathway driven by mutated NRAS or BRAF with specific BRAF- and MEK inhibitors, increases the median overall survival from metastasized melanoma patients from 9 months with no therapy to approximately 14 months with successful inhibitor treatment [3]. The gene discussed is MAP2K7; the disease is melanoma.